Literature DB >> 3967508

Aerosol delivery in intubated, mechanically ventilated patients.

N R MacIntyre, R M Silver, C W Miller, F Schuler, R E Coleman.   

Abstract

To study the effects of respiratory failure and mechanical ventilation on aerosol delivery to the lungs, we performed nuclear scans after aerosolization of 5 to 9 mCi of Tc-99m diethylenetriamine pentaacetic acid in seven stable, intubated, and mechanically ventilated patients. The radioactivity reaching the lungs was 2.9 +/- .7% (mean +/- SD) of the administered dose, an amount significantly less than that in three healthy nonintubated subjects and also less than what would be expected in nonintubated subjects from other published reports. We then performed a subsequent study in 15 additional mechanically ventilated patients who were receiving aerosolized bronchodilators through their endotracheal tube. In these patients, heart rate and lung mechanical function values before and after treatment were not significantly different. We conclude from these studies that aerosol delivery in mechanically ventilated patients is significantly reduced and that this is probably due to a combination of suboptimal breathing pattern, intrinsic airway disease, and the endotracheal tube functioning as both a site for aerosol deposition through impaction as well as a barrier to gastrointestinal absorption.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3967508     DOI: 10.1097/00003246-198502000-00005

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  29 in total

1.  Maximizing aerosol delivery during mechanical ventilation: go with the flow and go slow.

Authors:  Rajiv Dhand
Journal:  Intensive Care Med       Date:  2003-07       Impact factor: 17.440

2.  Magnetized aerosols comprising superparamagnetic iron oxide nanoparticles improve targeted drug and gene delivery to the lung.

Authors:  Guenther Hasenpusch; Johannes Geiger; Kai Wagner; Olga Mykhaylyk; Frank Wiekhorst; Lutz Trahms; Alexandra Heidsieck; Bernhard Gleich; Christian Bergemann; Manish K Aneja; Carsten Rudolph
Journal:  Pharm Res       Date:  2012-01-21       Impact factor: 4.200

3.  In vitro assessment of drug delivery through an endotracheal tube using a dry powder inhaler delivery system.

Authors:  M L Everard; S G Devadason; P N Le Souëf
Journal:  Thorax       Date:  1996-01       Impact factor: 9.139

Review 4.  Aerosolised antibacterials for the prevention and treatment of hospital-acquired pneumonia.

Authors:  G Christopher Wood; Joseph M Swanson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

5.  Nebulisation of surfactants in an animal model of neonatal respiratory distress.

Authors:  T F Fok; M al-Essa; M Dolovich; F Rasid; H Kirpalani
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1998-01       Impact factor: 5.747

6.  Effect of inhaled leukotriene B4 alone and in combination with prostaglandin D2 on bronchial responsiveness to histamine in normal subjects.

Authors:  P N Black; R W Fuller; G W Taylor; P J Barnes; C T Dollery
Journal:  Thorax       Date:  1989-06       Impact factor: 9.139

Review 7.  Aerosol delivery via invasive ventilation: a narrative review.

Authors:  Hui-Ling Lin; James B Fink; Huiqing Ge
Journal:  Ann Transl Med       Date:  2021-04

8.  Pulmonary deposition of a nebulised aerosol during mechanical ventilation.

Authors:  S H Thomas; M J O'Doherty; H M Fidler; C J Page; D F Treacher; T O Nunan
Journal:  Thorax       Date:  1993-02       Impact factor: 9.139

9.  Aerosol therapy during mechanical ventilation: an international survey.

Authors:  Stephan Ehrmann; Ferran Roche-Campo; Giuseppe Francesco Sferrazza Papa; Daniel Isabey; Laurent Brochard; Gabriela Apiou-Sbirlea
Journal:  Intensive Care Med       Date:  2013-03-23       Impact factor: 17.440

10.  Aerosolised surfactant generated by a novel noninvasive apparatus reduced acute lung injury in rats.

Authors:  Yu Sun; Rui Yang; Ji-gen Zhong; Feng Fang; Jin-jin Jiang; Ming-yao Liu; Jian Lu
Journal:  Crit Care       Date:  2009-03-04       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.